Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
Year: 2014
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet Neurology
Institutions: Mayo Clinic, Mayo Clinic in Arizona, Mayo Clinic Hospital, University of California, San Francisco, King's College London, Wellcome Trust, Thomas Jefferson University, Albert Einstein College of Medicine, University of Copenhagen, Glostrup Hospital, California Medical Clinic for Headache, Alder (United States)
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funders: Bristol-Myers Squibb, Migraine Research Foundation, National Headache Foundation, Eli Lilly and Company, Medtronic, Meso Scale Diagnostics, Zogenix, American Headache Society, National Institutes of Health, Allergan, Merck Sharp and Dohme, National Institute on Aging, National Institute of Neurological Disorders and Stroke
Awards: Gender and Hormonal Differences in Parkinson's Disease, Biomarkers in Early Alzheimer's Disease (AD)., Role of Genes in Exceptional Longevity in Humans, Einstein Aging Study, TWO PRECLINICAL LATENT SCORES TO PREDICT OCCURRENCE OF DAT, Predictors of Gait and Falls in Aging: Linking Cognitive Control to Genes, Latent Mobility Abnormalities And Frailty, G8784440921, G9000130269
OpenAlex ID: W2148445312
